The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes : a systematic review of randomised controlled trials. / Chan, Miin; Larsen, Nadja; Baxter, Helen; Jespersen, Lene; Ekinci, Elif I.; Howell, Kate.

I: Nutrition Research Reviews, 2023.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Chan, M, Larsen, N, Baxter, H, Jespersen, L, Ekinci, EI & Howell, K 2023, 'The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials', Nutrition Research Reviews. https://doi.org/10.1017/S0954422423000252

APA

Chan, M., Larsen, N., Baxter, H., Jespersen, L., Ekinci, E. I., & Howell, K. (2023). The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials. Nutrition Research Reviews. https://doi.org/10.1017/S0954422423000252

Vancouver

Chan M, Larsen N, Baxter H, Jespersen L, Ekinci EI, Howell K. The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials. Nutrition Research Reviews. 2023. https://doi.org/10.1017/S0954422423000252

Author

Chan, Miin ; Larsen, Nadja ; Baxter, Helen ; Jespersen, Lene ; Ekinci, Elif I. ; Howell, Kate. / The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes : a systematic review of randomised controlled trials. I: Nutrition Research Reviews. 2023.

Bibtex

@article{37726ad4233d4d26b3ec181cb7f22d66,
title = "The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes: a systematic review of randomised controlled trials",
abstract = "Our systematic review assessed the impact of botanical fermented food (BFF) consumption on glucose, lipid, anthropometric, inflammatory and gut microbiota parameters, in adults with metabolic syndrome (MetS), MetS components or type 2 diabetes mellitus (T2DM). Embase, MEDLINE, Cochrane CENTRAL and Google Scholar were searched with no language limits, from inception to August 31, 2022, for eligible randomised controlled trials (RCTs). Two independent reviewers screened 6873 abstracts and extracted relevant data. Risk of bias (ROB) was assessed using the Cochrane Collaboration's ROB2 tool. The final review included 26 RCTs, with 31 reports published between 2001 and 2022. Significant (p<0.05) within-group and between-group changes in cardiometabolic outcome means were reported in 23 and 19 studies, respectively. Gut microbiota composition was assessed in four studies, with two finding significant between-group differences. No significant difference between groups of any measured outcomes was observed in five studies. There were 14 studies at low ROB; ten were of some concern; and two were at high ROB. In 73% of included studies, BFF consumption by participants with obesity, MetS or T2DM led to significant between-group improvements in discrete cardiometabolic outcomes, including fasting blood glucose, lipid profile, blood pressure, waist circumference, body fat percentage, and C-reactive protein. BFF consumption increased the abundance of beneficial gut bacteria, such as Bifidobacterium and LAB, whilst reducing potential pathogens like Bacteroides. To determine the clinical significance of BFFs as therapeutic dietary adjuncts, their safety, tolerability and affordability must be balanced with the limited power and magnitude of these preliminary findings.",
keywords = "Botanical fermented foods, diabetes, glycaemic control, gut microbiota, inflammatory markers, metabolic syndrome, obesity, plant based, systematic review",
author = "Miin Chan and Nadja Larsen and Helen Baxter and Lene Jespersen and Ekinci, {Elif I.} and Kate Howell",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",
year = "2023",
doi = "10.1017/S0954422423000252",
language = "English",
journal = "Nutrition Research Reviews",
issn = "0954-4224",
publisher = "Cambridge University Press",

}

RIS

TY - JOUR

T1 - The impact of botanical fermented foods on metabolic syndrome and type 2 diabetes

T2 - a systematic review of randomised controlled trials

AU - Chan, Miin

AU - Larsen, Nadja

AU - Baxter, Helen

AU - Jespersen, Lene

AU - Ekinci, Elif I.

AU - Howell, Kate

N1 - Publisher Copyright: © The Author(s) 2023.

PY - 2023

Y1 - 2023

N2 - Our systematic review assessed the impact of botanical fermented food (BFF) consumption on glucose, lipid, anthropometric, inflammatory and gut microbiota parameters, in adults with metabolic syndrome (MetS), MetS components or type 2 diabetes mellitus (T2DM). Embase, MEDLINE, Cochrane CENTRAL and Google Scholar were searched with no language limits, from inception to August 31, 2022, for eligible randomised controlled trials (RCTs). Two independent reviewers screened 6873 abstracts and extracted relevant data. Risk of bias (ROB) was assessed using the Cochrane Collaboration's ROB2 tool. The final review included 26 RCTs, with 31 reports published between 2001 and 2022. Significant (p<0.05) within-group and between-group changes in cardiometabolic outcome means were reported in 23 and 19 studies, respectively. Gut microbiota composition was assessed in four studies, with two finding significant between-group differences. No significant difference between groups of any measured outcomes was observed in five studies. There were 14 studies at low ROB; ten were of some concern; and two were at high ROB. In 73% of included studies, BFF consumption by participants with obesity, MetS or T2DM led to significant between-group improvements in discrete cardiometabolic outcomes, including fasting blood glucose, lipid profile, blood pressure, waist circumference, body fat percentage, and C-reactive protein. BFF consumption increased the abundance of beneficial gut bacteria, such as Bifidobacterium and LAB, whilst reducing potential pathogens like Bacteroides. To determine the clinical significance of BFFs as therapeutic dietary adjuncts, their safety, tolerability and affordability must be balanced with the limited power and magnitude of these preliminary findings.

AB - Our systematic review assessed the impact of botanical fermented food (BFF) consumption on glucose, lipid, anthropometric, inflammatory and gut microbiota parameters, in adults with metabolic syndrome (MetS), MetS components or type 2 diabetes mellitus (T2DM). Embase, MEDLINE, Cochrane CENTRAL and Google Scholar were searched with no language limits, from inception to August 31, 2022, for eligible randomised controlled trials (RCTs). Two independent reviewers screened 6873 abstracts and extracted relevant data. Risk of bias (ROB) was assessed using the Cochrane Collaboration's ROB2 tool. The final review included 26 RCTs, with 31 reports published between 2001 and 2022. Significant (p<0.05) within-group and between-group changes in cardiometabolic outcome means were reported in 23 and 19 studies, respectively. Gut microbiota composition was assessed in four studies, with two finding significant between-group differences. No significant difference between groups of any measured outcomes was observed in five studies. There were 14 studies at low ROB; ten were of some concern; and two were at high ROB. In 73% of included studies, BFF consumption by participants with obesity, MetS or T2DM led to significant between-group improvements in discrete cardiometabolic outcomes, including fasting blood glucose, lipid profile, blood pressure, waist circumference, body fat percentage, and C-reactive protein. BFF consumption increased the abundance of beneficial gut bacteria, such as Bifidobacterium and LAB, whilst reducing potential pathogens like Bacteroides. To determine the clinical significance of BFFs as therapeutic dietary adjuncts, their safety, tolerability and affordability must be balanced with the limited power and magnitude of these preliminary findings.

KW - Botanical fermented foods

KW - diabetes

KW - glycaemic control

KW - gut microbiota

KW - inflammatory markers

KW - metabolic syndrome

KW - obesity

KW - plant based

KW - systematic review

U2 - 10.1017/S0954422423000252

DO - 10.1017/S0954422423000252

M3 - Review

C2 - 37881833

AN - SCOPUS:85176362269

JO - Nutrition Research Reviews

JF - Nutrition Research Reviews

SN - 0954-4224

ER -

ID: 374971042